@article{dc2ab6cf276646019bc3dabf385ece28,
title = "New findings from the bipolar collaborative network: Clinical implications for therapeutics",
abstract = "In this article, we highlight recent Bipolar Collaborative Network data. We found that childhood-onset bipolar illness is common, often goes untreated for more than a decade, and carries a poor prognosis. During randomized studies of adjunctive medications in depression: 1) Venlafaxine showed higher switch rates than bupropion or sertraline; 2) Tranylcypromine was as well tolerated as lamotrigine; and 3) Modafinil was more effective than placebo. Finally, in treatment of overweight and obesity, topiramate and sibutramine showed equal efficacy but poor tolerability, and zonisamide data showed that it may be useful for mood and weight loss.",
author = "Post, {Robert M.} and Altshuler, {Lori L.} and Frye, {Mark A.} and Trisha Suppes and Susan McElroy and Keck, {Paul E.} and Leverich, {Gabriele S.} and Ralph Kupka and Nolen, {Willem A.} and Heinz Grunze",
note = "Funding Information: Dr. Post has served as a consultant for AstraZeneca International and Shire US, Inc., as a consultant and on the speakers{\textquoteright} bureau for GlaxoSmithKline, and on the speakers{\textquoteright} bureau for Bristol-Myers Squibb. Dr. Altshuler has received grant/research support and honoraria from and served on the advisory board for Abbott Laboratories, received honoraria from Bristol-Myers Squibb, received honoraria from and served on the advisory board and speakers{\textquoteright} bureau for Forest Laboratories, Inc., and received honoraria from and served on the speakers{\textquoteright} bureau for GlaxoSmithKline. Dr. Frye has served as a consultant for Abbott Laboratories, AstraZeneca International, Bristol-Myers Squibb, Eli Lilly and Co., GlaxoSmithKline, Janssen-Cilag, Johnson & Johnson, Novartis Pharmaceuticals, Ortho-McNeil, Inc., Otsuka America Pharmaceutical, Inc., Pfizer, Inc., Shire US, Inc., Solvay Pharmaceuticals, Inc., and Wyeth; has received grants from Abbott Laboratories, the American Foundation for Suicide Prevention, Cephalon, Inc., GlaxoSmithKline, the NIMH, Pfizer, Inc., Solvay Pharmaceuticals, Inc., and the Stanley Medical Research Institute; and served on the speakers{\textquoteright} bureau for AstraZeneca International, Bristol-Myers Squibb, Eli Lilly and Co., Otsuka America Pharmaceutical, Inc., and Pfizer, Inc.",
year = "2006",
month = dec,
doi = "10.1007/s11920-006-0056-5",
language = "English (US)",
volume = "8",
pages = "489--497",
journal = "Current Psychiatry Reports",
issn = "1523-3812",
publisher = "Current Science, Inc.",
number = "6",
}